MIAMI, FLORIDA (OCT. 20, 2025) – A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

HIV is infamous for its ability to hide in the human body for decades, typically requiring long-term treatment to prevent a ...

Tislelizumab addition to CRT improved survival in ESCC, with group B showing a 1-year PFS rate of 73% and OS rate of 85%. The trial's primary endpoint was PFS, with secondary endpoints including OS, ...

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with BRCA-relat ...

New gene-editing project targets thalassemia’s root cause A new research project at the Cyprus Institute of Neurology and ...

When Adele Miner was five, and her mother seven months pregnant, she discovered her father was having an affair. Here she ...

From the 2010s to the present, the existing technologies in the clinic and operating room have been improved with the goals ...

The new luxury for the ultra-high-net-worth individual is not a product but time, driving a trillion-dollar global wellness ...

New research found that gene therapy for children with a form of severe combined immunodeficiency was successful in 95% of ...

Touted by longevity experts, celebrated by biohackers, and whispered about in elite wellness circles, NAD+ is the molecule at ...